- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
| home:othertreatments:birth_control [07.26.2011] – Removed duplicate wording, rephrased initial statement. joyful | home:othertreatments:birth_control [09.21.2011] – [Birth control] paulalbert | ||
|---|---|---|---|
| Line 2: | Line 2: | ||
| < | < | ||
| + | |||
| + | Women of childbearing age on the MP who do not want to risk the chance of bearing a child suffering from fetal or neonatal injury should take precautions to prevent pregnancy, as the FDA package insert lists these as complications of taking olmesartan during the second or third trimesters. According to the FDA, these adverse effects do not appear to have resulted from intrauterine drug exposure that has occurred only during the first trimester. | ||
| Because the MP can increase or restore fertility, women of childbearing age who are on the MP and sexually active are advised to use adequate precautions to avoid getting pregnant. | Because the MP can increase or restore fertility, women of childbearing age who are on the MP and sexually active are advised to use adequate precautions to avoid getting pregnant. | ||
| + | |||
| + | |||
| + | |||
| The doses of hormones found in birth control are low enough that patients need not be excessively concerned with their effect on immune function. | The doses of hormones found in birth control are low enough that patients need not be excessively concerned with their effect on immune function. | ||
home/othertreatments/birth_control.txt · Last modified: 01.03.2012 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.